Relapsed/refractory Lymphoma

9 clinical trials · Condition

Record	Firm	Date
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma (NCT05400876)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2022-06-09
Study of F527 in Patients With Relapsed or Refractory Lymphoma (NCT05293028)	Shandong New Time Pharmaceutical Co., LTD	2022-05-20
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (NCT05189093)	Hangzhou Hanx Biopharmaceuticals, Ltd.	2021-12-31
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors (NCT05271279)	Beijing Boren Hospital	2021-12-24
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma (NCT02259010)	Millennium Pharmaceuticals, Inc.	2014-10-22
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function (NCT02214147)	Millennium Pharmaceuticals, Inc.	2014-08-21

Every clearance here is in the API, with alerts when new ones post.